Phase 1 Study of Binimetinib Plus Pexidartinib for GIST

Share this content:
Researchers are investigating the safety and tolerability of binimetinib plus pexidartinib among patients with a gastrointestinal stromal tumor.
Researchers are investigating the safety and tolerability of binimetinib plus pexidartinib among patients with a gastrointestinal stromal tumor.

Title: A Phase I Study of Binimetinib in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)1

Principal Investigators: Ping Chi, MD, PhD, Memorial Sloan Kettering Cancer Center

Description: For this open-label phase 1 study (ClinicalTrials.gov Identifier: NCT03158103), researchers are investigating the safety and tolerability of binimetinib (an MEK inhibitor) plus pexidartinib (a CSF-1R inhibitor) among patients with a GIST.

Patients will receive oral pexidartinib twice daily (400 mg in the morning and 200 mg in the evening) for 2 weeks followed by binimetinib 30 mg twice daily with pexidartinib throughout a 28-day treatment cycle. Varying doses of each medication will be administered.

The primary outcome is to determine the recommended phase 2 dose (RP2D) after 1 year of treatment; the 3+3 format will be used to guide dose escalation based on toxicities observed in the first cycle of therapy. Secondary outcome measures include the number of participants with a complete or partial response.

The estimated study enrollment is 40 patients.

For more study information, including inclusion and exclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT03158103.

Status: Open and recruiting patients as of November 22, 2017.

This study is sponsored by Memorial Sloan Kettering Cancer Center, in collaboration with Array BioPharma and Plexxikon.

Reference

  1. Clinicaltrials.gov. A Study of MEK162 (Binimetinib) in combination with pexidartinib in patients with advanced gastrointestinal stromal tumor (GIST). NCT03158103. https://clinicaltrials.gov/ct2/show/NCT03158103. Accessed November 21, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters